CASTLE BIOSCIENCES INC(CSTL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

CASTLE BIOSCIENCES INC (CSTL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CSTL at 40.7/100 on a 32-signal composite quality model, placing it at rank #2,093 of 2,962 stocks — the bottom half of the AI-ranked universe. CSTL scores in the top quartile across earnings quality (85.5). Areas of concern include institutional flow (14.7) and profitability (23.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CASTLE BIOSCIENCES INC reports quarterly revenue of $103.5M, net income of $-2.1M, free cash flow of $6.6M. Top institutional holders of CSTL by reported 13-F value include BlackRock, RTW INVESTMENTS, PRINCIPAL FINANCIAL GROUP, based on the most recent SEC filings. CSTL trades on the Nasdaq exchange and files with the SEC under CIK 1447362. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CSTL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CASTLE BIOSCIENCES INC directly from SEC EDGAR.